Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its diabetes drug Mounjaro.
Related Posts
Morgan Stanley upgrades this commercial real estate stock, sees nearly 30% upside ahead
The bank upgraded the commercial real estate services stock to overweight from equal weight.
How to keep your portfolio steady in volatile times as the election approaches
Market volatility is expected to pick up as Election Day approaches, but investors can take a few steps to help prepare their portfolios.
UBS names its top retail stock picks this holiday shopping season
Research shows consumers want to spend this holiday season. These are the so-called ‘softline’ retail names on the UBS buy list.